ONS Congress® Scholarships | Oncology Nursing Foundation

ONS Congress Scholarships are supported by the Oncology Nursing Foundation, Nancy Berkowitz Scholarship Fund, Ron Schlesinger Scholarship Fund, Oncology Hematology Care, Inc., Siouxland Chapter fund, CEBONS Karen Zapotoski Memorial ONS Congress Scholarship, and Susie Maloney Scholarship Fund. Applications Open: September 15, 2024 Applications Due: December 1, 2024 Applicants Notified: End of February 2025 Note for International Applicants: If you intend to apply, please be sure to apply for your travel

Read the full article here

Source: www.onfgivesback.org

Categories: Hem/Oncs, General Medicine News

Tags: ONSCongress,ONFGivesBack,ONFImpact

Tweets with this article

Darcy Burbage, DNP, RN, AOCN

#ONSCongress scholarship applications are now open! The 50th Annual @oncologynursing Conference is scheduled for 4/9-4/23/2025 in Denver. You don’t want to miss this incredible event! Apply today at the link 🔗 below ⤵️ https://t.co/RZihKfEqxv #ONFGivesBack #ONFImpact https://t.co/VI1pCDJwB7

Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey – PubMed

Chatbots are artificial intelligence (AI) programs designed to simulate conversations with humans that present opportunities and challenges in scientific research. Despite growing clarity from publishing…

Dr.Alberto Mussetti November 25, 2024

Now, where did I put my glasses?

A common medical term is sequela. You pronounce it like this: seh-QWEL-uh. And it means the after-effects of a disease. In other words, a medical…

Edward Creagan MD November 25, 2024

ASCO Election

Tatiana Prowell, MD November 25, 2024

Durvalumab, tremelimumab and platinum chemotherapy in EGFR mutation positive non-small cell lung cancer – an open label phase 2 trial (ILLUMINATE)

EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of…

Stephen V Liu November 25, 2024

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a…

Daniel Castellano November 25, 2024

Conflicts of interest: moving towards zero tolerance

Harmful industries still exert their influence over health professionals, academia, and health systems; robust change is required, write Chris van Tulleken, Nigel Rollins, and Rebecca…

Ash Paul November 25, 2024

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Daniel Castellano November 25, 2024

Adobe Acrobat – s40279-023-01989-9.pdf

Click or tap to view this file.

Ash Paul November 25, 2024

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Daniel Castellano November 25, 2024

Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma

Background: Inactivating TP53 mutations in mantle cell lymphoma (MCL) are associated with poor prognosis. While next-generation sequencing (NGS) is the gold standard for assessing TP53…

Raul Cordoba, MD, PhD November 25, 2024

Related Articles